Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycansFootnote

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CHO, Chinese hamster ovary; Endo, endo-β-N-acetylglucosaminidase; Fc, fragment crystallizable; FcγRIIIa, Fcγ receptor type IIIa; HPLC, high-performance liquid chromatography; IgG, immunoglobulin G; K_D, dissociation constants; LC-MS/MS, liquid chromatography-tandem mass spectrometry; mAb, monoclonal antibody; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; Oxa, oxazoline; RLU, relative luminescence unit; SPR, surface plasmon resonance.

References

• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–1453.10.1016/0161-5890(93)90106-L
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285–4289.10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult t-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520–1531.10.1158/1078-0432.CCR-09-2697
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005;21:11–16.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.10.1038/nri2206
   PubMed Web of Science ®Google Scholar
• Huber R, Deisenhofer J, Colman PM, et al. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature. 1976;264:415–420.10.1038/264415a0
   PubMed Web of Science ®Google Scholar
• Wormald MR, Rudd PM, Harvey DJ, et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic Motion of the Fc oligosaccharides. Biochemistry. 1997;36:1370–1380.10.1021/bi9621472
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325:979–989.10.1016/S0022-2836(02)01250-0
   PubMed Web of Science ®Google Scholar
• Kobata A. The N-linked sugar chains of human immunoglobulin G: Their unique pattern, and their functional roles. Biochim Biophys Acta. 2008;1780:472–478.10.1016/j.bbagen.2007.06.012
   PubMed Web of Science ®Google Scholar
• Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176–180.
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005;21:1644–1652.10.1021/bp050228w
   PubMed Web of Science ®Google Scholar
• Huang W, Giddens J, Fan SQ, et al. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc. 2012;134:12308–12318.10.1021/ja3051266
   PubMed Web of Science ®Google Scholar
• Kurogochi M, Mori M, Osumi K, et al. Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcγRIIIa and variable antibody-dependent cellular cytotoxicity activities. PLoS One. 2015;10:e0132848.10.1371/journal.pone.0132848
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–26740.10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–3473.10.1074/jbc.M210665200
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87:614–622.10.1002/(ISSN)1097-0290
   PubMed Web of Science ®Google Scholar
• Eshima Y, Higuchi Y, Kinoshita T, et al. Transglycosylation activity of glycosynthase mutants of Endo-β-N-acetylglucosaminidase from coprinopsis cinerea. PLoS One. 2015;10:e0132859.10.1371/journal.pone.0132859
   PubMed Web of Science ®Google Scholar
• Collin M, Olsen A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 2001;20:3046–3055.10.1093/emboj/20.12.3046
   PubMed Web of Science ®Google Scholar
• Noguchi M, Tanaka T, Gyakushi H, et al. Efficient synthesis of sugar oxazolines from unprotected N-Acetyl-2-amino sugars by using chloroformamidinium reagent in water. J Org Chem. 2009;74:2210–2212.10.1021/jo8024708
   PubMed Web of Science ®Google Scholar
• Wang S, Ionescu R, Peekhaus N, et al. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J Chromatogr A. 2010;1217:6496–6502.10.1016/j.chroma.2010.08.044
   PubMed Web of Science ®Google Scholar
• Kurogochi M, Amano J. Relative quantitation of glycopeptides based on stable isotope labeling using MALDI-TOF MS. Molecules. 2014;19:9944–9961.10.3390/molecules19079944
   PubMed Web of Science ®Google Scholar
• Parekh BS, Berger E, Sibley S, et al. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. mAbs. 2012;4:310–318.10.4161/mabs.19873
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010;70:4481–4489.10.1158/0008-5472.CAN-09-3704
   PubMed Web of Science ®Google Scholar
• Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J. 1991;5:2684–2690.
   PubMed Web of Science ®Google Scholar
• Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005;24:487–499.10.1007/s10555-005-6192-2
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The Impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.10.1146/annurev.immunol.25.022106.141702
   PubMed Web of Science ®Google Scholar
• Kobata A. Function and pathology of the sugar chains of human immunoglobulin G. Glycobiology. 1990;1:5–8.10.1093/glycob/1.1.5
   PubMedGoogle Scholar
• Koide N, Nose M, Muramatsu T. Recognition of IgG by Fc receptor and complement: Effects of glycosidase digestion. Biochem Biophys Res Commun. 1977;75:838–844.10.1016/0006-291X(77)91458-9
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Endo T, Matsuta K, et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol. 1989;16:285–290.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108:12669–12674.10.1073/pnas.1108455108
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–234.10.1038/nrd2804
   PubMed Web of Science ®Google Scholar
• Li T, DiLillo DJ, Bournazos S, et al. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci USA. 2017;114:3485–3490.10.1073/pnas.1702173114
   PubMed Web of Science ®Google Scholar
• Giddens JP, Lomino JV, Amin MN, et al. Endo-F3 glycosynthase mutants enable chemoenzymatic synthesis of core-fucosylated triantennary complex type glycopeptides and glycoproteins. J Biol Chem. 2016;291:9356–9370.10.1074/jbc.M116.721597
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39:271–278.10.1007/s12026-007-0073-4
   PubMed Web of Science ®Google Scholar
• Li C, Rossomando A, Wu SL, et al. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. mAbs. 2013;5:565–575.10.4161/mabs.24814
   PubMed Web of Science ®Google Scholar